The right clinical trial tech stack isn’t the most complete one; it’s the one built with sites, funded fairly, and designed to remove friction, not add it.
- The Risks And Unresolved Rules Of Real-Time Clinical Trials
- What Real-Time Clinical Trials Demand From Your Tech Stack
- The FDA's RTCT Push: What It Is; Why It Matters
- Pharma's Digital Transformation: Where It's Really At
- How AI Is Changing Clinical Trial Design, Not Just Speed
- What Is Clinical Trials Day? Why Technology Helps Research Rise
- DiMe's Navigator: Why Teams Still Stall On Digital Endpoints
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
RTSM/IRT In Clinical Trials: The Complete Guide
RTSM/IRT systems are essential to modern clinical trials. This guide explores how to implement and optimize them to boost efficiency, streamline operations, uphold study integrity, and ensure compliance.
-
How To Reduce Risk And Effort When Migrating A TMF
Utilize this summary of key tips, checklists, and lessons learned to mitigate the risks and efforts associated with migrating a trial master file.
-
With The Emergence Of DCTs, Do We Really Need A CTMS?
As decentralized trial designs continue to grow in popularity, do sponsors and CROs really need a clinical trial management system? Explore whether CTMS is necessary with the emergence of DCTs.
-
Paper COAs in 2026: It's Not Cheaper, It's Riskier
Learn why sticking with paper records is a faulty strategy and discover how hidden costs, transcription errors, and regulatory red flags make digital COAs the only safe choice for modern trials.
-
eCOA Predictions For 2022
Dive into the prediction that the rapid adoption of eCOAs will continue to grow in 2022, as sponsors acknowledge how useful these tools have become in decentralized clinical trial (DCT) settings.
-
Medable's Japanese Clinical Trial Exceeds FPI Date And eCOA Adherence
A top-10 global pharma company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites in Japan. Explore an initiative to enhance the patient and site experience.
-
AI Won't Fix Clinical Development Until Pharma Changes How They Use It
Clinical development teams can unlock real AI value by aligning it to roles, workflows, and accountability. A practical operating model shows how to cut cycle time, reduce rework, and strengthen GxP‑ready decisions.
-
Real-World Data Vs. Real-World Evidence
Unearth the ways real-world data (RWD) and real-world evidence (RWE) in clinical R&D can be used to provide additional validation for new therapies and drugs regarding their efficacy, safety, and value.
-
Unlocking Scalability In Pharma With AI
Uncover how artificial intelligence and machine learning could emerge as the most pivotal technologies of our era, with the potential to facilitate scalability in pharmaceuticals and other industries.
-
How To Reduce Eligibility Risk And Prevent Protocol Deviations
Eliminate enrollment-based protocol deviations and align with the latest FDA guidance by implementing a centralized, technology-enabled eligibility review to safeguard trial integrity.
RECENT NEWSLETTERS
- 06.11.26 -- AI Governance, Site Tech Risk, And Trial Efficiency Gains
- 06.06.26 -- Best Of May: AI Risk, CRO Strategy, And Trial Cost Control
- 06.04.26 -- Why Clinical Execution — Not Tech — Is Trials' Biggest Risk
- 05.28.26 -- FDA's Elsa AI Shift, RTCT Rules, And RWE That Works
- 05.21.26 -- AI, HEOR, And Hidden Costs Reshaping Clinical Trials